SRSF7

Across TCGA pan-cancer cohorts, SRSF7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRSF7 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SRSF7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRSF7 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where SRSF7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.693	0.859	.001	63	view →
LSCC	DFS	Median	All	0.832	0.599	.004	44	view →
PDAC	OS	Median	III,IV	0.589	0.921	.019	12	view →
LUAD	OS	Median	III,IV	0.683	0.210	.009	8	view →
CCRCC	DFS	Quartile	All	0.705	0.951	.006	6	view →
GBM	OS	Median	All	0.557	0.286	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRSF7–HNSC (DFS)

Open the HNSC breakdown →